Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED

大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

RESULTS OF THE RIGHTS ISSUE ON THE BASIS OF FOUR (4) RIGHTS SHARES FOR EVERY ONE (1) ADJUSTED SHARE HELD ON THE RECORD DATE

References are made to the prospectus of Universal Health International Group Holding Limited (the "**Company**") dated 5 October 2026 (the "**Prospectus**") and the announcement of the Company dated 23 October 2026 (the "**Announcement**") in relation to the Rights Issue. Capitalised terms used herein shall have the same meanings as those defined in the Prospectus, unless the context otherwise requires.

RESULTS OF THE RIGHTS ISSUE AND THE COMPENSATORY ARRANGEMENTS

As disclosed in the Announcement, as at 4:00 p.m. on Tuesday, 20 October 2026, being the Latest Time for Acceptance, a total of 19 valid applications had been received for a total of 106,946,253 Rights Shares, representing approximately 24.18% of the total number of Rights Shares offered under the Rights Issue. The remaining 335,242,619 Unsubscribed Rights Shares, representing approximately 75.82% of the total number of Rights Shares offered under the Rights Issue, would be subject to the Compensatory Arrangements.

The Board wishes to announce that, as at 4:00 p.m. on Friday, 30 October 2026, being the latest time of placing of the Unsubscribed Rights Shares by the Placing Agent, all the 335,242,619 Unsubscribed Rights Shares were successfully placed at the price of HK$0.40 per Adjusted Share, which is equal to the Subscription Price, under the Placing. Accordingly, there is no Net Gain available to be distributed to the No Action Shareholders under the Compensatory Arrangements.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, (i) each of the placees and where appropriate, their respective ultimate beneficial owner(s), is an Independent Third Party; and (ii) none of the placees has become a substantial shareholder of the Company (as defined under the Listing Rules) upon completion of the Placing.

As all the conditions with respect to the Rights Issue as set out in the Prospectus have been fulfilled, the Rights Issue became unconditional at 4:00 p.m. on Saturday, 31 October 2026.

Accordingly, the net proceeds from the Rights Issue (including the Compensatory Arrangements) were approximately HK$176.9 million, and the estimated net proceeds from the Rights Issue after deducting all necessary expenses will be approximately HK$172.3 million. Assuming no material fluctuations in the stock market, the Company intends to apply (i) approximately HK$80.0 million will be utilized for the acquisition of controlling interest in a specified traditional Chinese medicine (TCM) manufacturer located in Hong Kong; and (ii) the remaining of approximately HK$92.3 million will be applied as general working capital for the Group's ongoing operations. This will be allocated across the following key operational areas:

(a) approximately HK$15.0 million for merchandising medicine and healthcare products for retail sale, which is expected to be fully utilised by 31 December 2026;

(b) approximately HK$14.0 million for rental expenses for the Group's business premises, covering approximately 7 months;

(c) approximately HK$7.5 million for professional fees, staff salaries, and other routine administrative expenses, which is expected to be fully utilised by 30 June 2027; and

(d) the balance, estimated to be approximately HK$55.8 million, to be allocated for the following other working capital and corporate purposes:

    (i) approximately HK$25.0 million for the repayment of the Group's outstanding bank borrowings and other interest-bearing liabilities, which will reduce the Group's finance costs and improve its overall financial position and is expected to be fully utilised by 31 December 2026;

    (ii) approximately HK$15.0 million as a reserve for potential strategic investments or business development initiatives that may arise, including but not limited to ecommerce business. As at the date of this Prospectus, there was no concrete plan for such investments and business; and

    (iii) the remaining balance of HK$15.8 million to be retained as a general liquidity reserve to provide the Group with financial flexibility to respond to unforeseen circumstances or market opportunities.

EFFECT OF THE RIGHTS ISSUE ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the following table sets out the shareholding structure of the Company immediately before and after the completion of the Rights Issue:

Name of Shareholders	**Immediately before completion of the Rights Issue**		**Immediately upon completion of the Rights Issue**	
	Number of Shares	*Approximate %*	*Number of Shares*	*Approximate %*
Mr. Chu *(Executive Director)* and his associates	9,812,099	8.88	49,060,495	8.88
Mr. Zhao *(Executive Director)*	34,340	0.03	171,700	0.03
Mr. Jin *(Executive Director)*	30,000	0.03	150,000	0.03
Public Shareholders	100,669,779	91.06	503,348,895	91.06
Total	**110,546,218**	**100**	**552,731,090**	**100**

DESPATCH OF SHARE CERTIFICATES FOR THE RIGHTS SHARES

Share certificates for all fully-paid Rights Shares are expected to be posted to those entitled thereto by ordinary post, at their own risk, to their registered addresses on Wednesday, 4 November 2026.

COMMENCEMENT OF DEALINGS IN FULLY-PAID RIGHTS SHARES

Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange at 9:00 a.m. on Thursday, 5 November 2026.

By order of the Board
Universal Health International Group Holding Limited
Chu Chuanfu
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 3 November 2026

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Chu Chuanfu, Mr. Jin Dongkun and Mr. Zhao Zehua and three independent non-executive directors, namely Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.